(Clinical Infectious Diseases Advance Access publication published June 18, 2014)  Summary:  Median dolutegravir concentrations in cerebrospinal fluid were similar to unbound dolutegravir concentrations in plasma and in all subjects exceeded the in vitro 50% inhibitory concentration for wild-type viruses (0.2 ng/mL) by ≥ 66-fold, suggesting that dolutegravir achieves therapeutic concentrations in cerespinal fluid.  HIV-1 SuperLow Viral Load assay on CSF samples performed by bioMONTR Labs.